Listen to more stories on the Noa app. The ad that Hims & Hers Health plans to air during the Super Bowl comes at you with rapid-fire visual overload—a giant jiggling belly, bare feet on scales ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...

In this article, we are going to take a look at where Hims & Hers Health Inc. (NYSE:HIMS) stands against other firms that posted double-digit gains on Thursday. Wall Street’s main indices ...

Hims and Roman are telehealth companies that sell prescription and nonprescription products to treat erectile dysfunction (ED), hair loss, and premature ejaculation (PE). Both ED and hair loss can ...

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth company. A big part of that is related to its Super Bowl LIX ad ...

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $60.30, moving +1.88% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.01%.

Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticized the ...